Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

The FDA has approved Gvoke VialDx (glucagon) for IV use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the GI tract.

While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...